Denali Therapeutics Inc. (DNLI) Shareholders’ equity 2016–2025
Denali Therapeutics Inc. (DNLI) shareholders’ equity at each fiscal year-end, per SEC filings.
$1.0BFY2025 · since FY2016: -$94.2M → $1.0B
| Fiscal year | Value | YoY |
|---|---|---|
| FY2025 | $1.0B | -17.6% |
| FY2024 | $1.2B | +19.3% |
| FY2023 | $1.0B | -1.1% |
| FY2022 | $1.0B | +8.3% |
| FY2021 | $962.3M | -16.4% |
| FY2020 | $1.2B | +191.4% |
| FY2019 | $394.9M | -27.8% |
| FY2018 | $546.8M | +17.4% |
| FY2017 | $465.8M | +594.7% |
| FY2016 | -$94.2M | — |
Source: SEC XBRL filings · For reference only · Not investment advice